Clinical Trial

Allergy Delabeling in Antibiotic Stewardship - Intervention

Study acronym: RENEW-IN
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy.
Protocol Amendment History 3 changes
critical Phase changed: not applicable -> Phase 4 2026-06-18
notable Sponsor changed: Ebbing Lautenbach -> Abramson Cancer Center at Penn Medicine 2026-06-18
critical Recruitment opened 2026-04-23
Trial Details
NCT Number NCT07133074
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: University of Utah
Conditions Beta Lactam Allergy, Hematologic Malignancy
Enrollment 3,800 participants
Start Date 2026-04-20
Primary Completion 2028-11 (estimated)
Study Completion 2029-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-17